Study wrapper · #541
Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation.
Editor's note
This is a preclinical rat study of GHRP-6, a growth-hormone-secretagogue hexapeptide, in a permanent coronary-ligation (non-reperfused) heart-attack model. After establishing a minimum effective dose in healthy rats, researchers reported that 7 days of GHRP-6 was associated with reduced myocardial tissue loss, less interstitial fibrosis/scarring, and improved left-ventricular function versus saline controls, with proteomic analysis pointing to fatty-acid oxidation, anti-apoptotic, antioxidant, and mitochondrial pathways. This is a small, short-duration rodent model with imaging, histology, and mechanistic proteomics as endpoints — a coherent preclinical cardioprotection signal, not clinical proof. These are preclinical findings; human data are needed before clinical conclusions can be drawn. GHRP-6's cardiovascular evidence remains at the animal-model stage.
Plain-language abstract
Researchers tested GHRP-6, a small peptide that prompts growth-hormone release, in rats given a heart attack by permanently tying off a coronary artery. After first finding the lowest dose that strengthened heart pumping in healthy rats, they treated the injured rats for 7 days and then examined their hearts with ultrasound and under the microscope. Compared with untreated animals, GHRP-6 was associated with less heart-muscle damage, less scarring, and better overall function of the heart's main pumping chamber. Analysis of heart-cell energy factories (mitochondria) suggested the benefit may come from improved fat-burning for energy, protection against cell death, and stronger antioxidant defenses. This was an animal study over just one week; the findings point to a possible protective effect but describe rat biology and cannot be applied to people without human research.